Rucaparib: A Targeted Therapy for Ovarian and Prostate Cancer

daisymiller

Rucaparib is an FDA-approved poly (ADP-ribose) polymerase (PARP) inhibitor used for the treatment of advanced ovarian and prostate cancers. It works by blocking the PARP enzyme, which helps cancer cells repair damaged DNA. By inhibiting this process, Rucaparib prevents cancer cells from repairing themselves, leading to their destruction. This targeted approach makes it effective especially in patients with BRCA1/2 gene mutations.

This oral medication is typically prescribed for patients who have undergone prior chemotherapy. It helps in delaying disease progression and improving survival rates. While generally well-tolerated, common side effects of Rucaparib include nausea, fatigue, anemia, and changes in liver function. Regular monitoring by healthcare providers ensures effective treatment management.

India is a major hub for pharmaceutical production, offering high-quality generic cancer medications at affordable prices. If you are looking for a  Rucaparib manufacturer , several Indian pharmaceutical companies produce and supply this vital oncology drug in compliance with international quality standards. These manufacturers ensure the global availability of cost-effective Rucaparib, making it more accessible for cancer patients worldwide.

With ongoing research and advancements, Rucaparib continues to play a crucial role in targeted cancer therapy, offering new hope to patients battling advanced-stage cancers.